U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry RACEMIC
Molecular Formula C22H17Cl2F6N3O3
Molecular Weight 556.285
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FLURALANER

SMILES

CC1=CC(=CC=C1C(=O)NCC(=O)NCC(F)(F)F)C2=NOC(C2)(C3=CC(Cl)=CC(Cl)=C3)C(F)(F)F

InChI

InChIKey=MLBZKOGAMRTSKP-UHFFFAOYSA-N
InChI=1S/C22H17Cl2F6N3O3/c1-11-4-12(2-3-16(11)19(35)31-9-18(34)32-10-21(25,26)27)17-8-20(36-33-17,22(28,29)30)13-5-14(23)7-15(24)6-13/h2-7H,8-10H2,1H3,(H,31,35)(H,32,34)

HIDE SMILES / InChI

Molecular Formula C22H17Cl2F6N3O3
Molecular Weight 556.285
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description

Fluralaner, isoxazoline class compound, is a systemic insecticide and acaricide with antiparasitic activity against cat and dog fleas and ticks. Fluralaner is an inhibitor of the arthropod nervous system. Fluralaner inhibits γ-aminobutyric acid (GABA)-gated chloride channels (GABACls) and L-glutamate-gated chloride channels (GluCls). Potency of fluralaner is comparable to fipronil (a phenylpyrazole ectoparasiticide). The U.S. Food and Drug Administration (FDA) approved it under the trade name Bravecto for flea and tick treatment and prevention in dogs in May 2014. Bravecto kills adult fleas and is indicated for the treatment and prevention of flea infestations (Ctenocephalides felis) and the treatment and control of tick infestations [Ixodes scapularis (black-legged tick), Dermacentor variabilis (American dog tick), and Rhipicephalus sanguineus (brown dog tick)] in dogs and puppies 6 months of age and older. Bravecto is also indicated for the treatment and control of Amblyomma americanum (lone star tick) infestations in dogs and puppies 6 months of age and older.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
1.6 nM [IC50]
0.45 nM [IC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Bravecto
Curative
Bravecto

PubMed

Sample Use Guides

In Vivo Use Guide
Administered topically as a single dose every 12 weeks to provide a minimum dose of 11.4 mg/lb (25 mg/kg) body weight.
Route of Administration: Topical
In Vitro Use Guide
Two-electrode voltage clamp electrophysiology was used to confirm that A1443 blocks GABA- and glutamate-induced chloride currents in Xenopus oocytes expressing MdGBCl or MdGluCl channels, with IC50 values of 5.32 and 79.9 nM, respectively.
Substance Class Chemical
Record UNII
WSH8393RM5
Record Status Validated (UNII)
Record Version